Scilex (SCLX) Projected to Post Earnings on Monday

Scilex (NASDAQ:SCLX) will likely be releasing its earnings data before the market opens on Monday, March 10th. Analysts expect Scilex to post earnings of ($0.10) per share and revenue of $17.87 million for the quarter.

Scilex (NASDAQ:SCLX) last posted its earnings results on Friday, January 17th. The company reported ($0.18) earnings per share (EPS) for the quarter. On average, analysts expect Scilex to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Scilex Stock Performance

Scilex stock opened at $0.30 on Wednesday. Scilex has a one year low of $0.21 and a one year high of $2.30. The company has a 50-day simple moving average of $0.40 and a 200-day simple moving average of $0.69. The firm has a market capitalization of $73.16 million, a P/E ratio of -0.36 and a beta of 1.06.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a “buy” rating and issued a $22.00 price target on shares of Scilex in a research note on Friday, February 28th.

Scilex Company Profile

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.